Abstract
Absorbed doses to red marrow and blood from 131I therapy were reevaluated using data which became available recently. Uncertainties in the calculations are discussed and a comparison is made with previously published dose estimates. The mean dose to red marrow from the treatment of [human] hyperthyroidism is estimated to be 0.59 rad mCi-1, compared with 0.36 rad mCi-1 for the euthyroid state. [Leukemia incidence in 131I treated hyperthyroid or carcinoma patients is discussed.].

This publication has 7 references indexed in Scilit: